Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease, with Everolimus receiving approval for ...

Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

PharmaScroll announced a new generative AI chatbot called Self-Serve AI. 1 The company describes it as a research and ...

Expanded GTM services aim to ensure members receive tests at the optimal times while cutting down on testing misuse.

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...